期刊文献+

骨肉瘤化疗后bcl-2表达与影像学改变及预后的相关性研究

Bcl-2 expression in osteosarcoma after chemotherapy: correlation with radiographic change and prognosis
下载PDF
导出
摘要 目的:探讨骨肉瘤化疗后bcl-2表达与影像学改变及预后的相关性。方法:23例病人均经穿刺活检病理证实为骨肉瘤,术前均按大剂量甲氨蝶呤(MMIA)方案化疗。免疫组化检测bcl-2,评价其与影像学改变及预后的相关性。结果:化疗前73.9%(17H23)患者bcl-2表达呈阳性,化疗后39.1%(9H23)呈阳性,差异具有显著统计学意义(χ2=15.36,P<0.05)。化疗前平均5.96分,化疗后平均8.65分,化疗后评分显著高于化疗前(t=4.236,P=0.000)。12例预后良好者,化疗前33.3%表达阳性,化疗后bcl-2阳性者8.3%;预后差者化疗前44.4%、化疗后33.3%表达阳性。结论:化疗后骨肉瘤bcl-2表达低于化疗前。化疗后bcl-2阳性表达率低者影像学评分高、预后好。 Objective: To correlate bcl-2 expression after chemotherapy in osteosareoma with radiographic change and prognosis. Methods: Large dose of MMIA chemotherapy was given to 23 patients with pathologically proved osteosareoma preoperatively. Bcl-2 was examined using immunohistology chemistry before and after chemotherapy. Expression of bcl-2 was correlated with change of radiography and prognosis. Results: Bcl-2 was positive in 73.9% and 39.1% of patients before and after chemotherapy respectively. There was a statistically difference between the two groups. Mean score of radiography before chemotherapy was statistically higher than that after chemotherapy, which was 5.96 scores and 8.65 scores respectively. In 12 patients with good prognosis, bcl-2 was positive in 33.3% and 8.3% before and after chemotherapy respectively. While that in patients with bad prognosis was 44.4% and 33.3% respectively. Conclusion: Expression of bcl-2 after chemotherapy decreased compared to that before chemotherapy. Osteosarcoma with less expression of bcl-2 had a higher score of radiograph and better prognosis.
作者 蔡懿
出处 《中国临床医学影像杂志》 CAS 北大核心 2006年第3期140-142,共3页 Journal of China Clinic Medical Imaging
关键词 骨肉瘤 药物疗法 基因 BCL-2 放射摄影术 osteosarcoma drug therapy genes, bcl-2 radiography
  • 相关文献

参考文献6

  • 1Ochi K,Daigo Y,Katagiri T,et al.Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene expression profiles[J].Int J Oncol,2004,24(3):647-655.
  • 2吴宁,张伟滨.骨肉瘤化疗疗效的评估[J].国外医学(骨科学分册),2003,24(3):142-145. 被引量:2
  • 3黄涛,吕刚,高大新,杨茂伟,王岩峰.Fas和bcl-2在骨肉瘤中的表达对其发生和预后的意义[J].中国临床康复,2004,8(29):6408-6409. 被引量:2
  • 4Merimsky O,Kollender Y,Issakov J,et al.Induction chemotherapy for bone sarcoma in adults:correlation of results with erb4 expression[J].Oncol Rep,2003,10(5):1593-1599.
  • 5杨迪生,范顺武,陶惠民,叶招明,何荣新.骨肉瘤辅助化疗方案的中、远期疗效观察[J].中华骨科杂志,2000,20(1):35-39. 被引量:27
  • 6Ilhan IE,Vural G,Berberoglu S,et al.Quantitative thallium-201 scintigraphy in childhood osteosarcoma:comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response[J].Pediatr Hematol Oncol,2005,22(2):153-162.

二级参考文献39

  • 1夏贤良,杨迪生,范顺武,陈其昕.骨肉瘤的治疗──117例回顾[J].中华骨科杂志,1994,14(2):79-82. 被引量:14
  • 2[1]Shimonishi T, Isse K, Shibata F, et al. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of introhepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000; 32(4pt1 ):761 -9
  • 3[2]Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002; 9 (4): 823 -7
  • 4[3]Kornmann M, Ishiwata T, Kleeff J, et al. Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg 2000; 231 (3): 368 - 79
  • 5[6]Huang SC, Tang M J, Hsu KF, et al. Fas and its ligand, caspases, and bcl-2expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma. J Clin Endocrinol Metab 2002; 87 (10): 4580 - 6
  • 6[7]Schulze-osthoff K, Ferrari D , Los M, et al, Apoptosis signaling by death receptors. Eur J Biochem 1998; 254:439 - 59
  • 7杨迪生,范顺武,陶惠民,叶招明.次全切除和异体骨支撑植骨治疗儿童孤立性骨囊肿[J].中国矫形外科杂志,1997,4(2):133-133. 被引量:5
  • 8Davis AM, Bell RS, Goodwin PJ. J Clin Onco1,1994,12(2):423~431.
  • 9Winkler K, Beron G, Delling G, et al. J Clin Oncol,1988,6(2):329~337.
  • 10Holscher HC, Bloem JL, Nooy MA, et al. A JR Am J Roentgenol,1990, 154(4):763~769.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部